#AORT Artivion Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/AORT/artivion-repor...

#AORT Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial

www.stocktitan.net/news/AORT/artivion-annou...

-AORT- Character concept 02

Name: Gdn

A very Important individual that guides the main character through the story.

#horror #indiegame #gamedev #AORT

-AORT- Character concept 01

Name: Ydin-06

#horror #indiegame #gamedev #AORT

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results Artivion (NYSE: AORT) will release third quarter 2025 financial results on Thursday, November 6, 2025 after market close, with a teleconference and live webcast at 4:30 p.m. ET.Pat Mackin, Chairman, President and CEO, will host the call and Q&A. To join live, dial 201-689-8261 a few minutes before 4:30 p.m. ET. A replay will be available about one hour after the event via toll-free 877-660-6853 or 201-612-7415 using conference number 13755945. The live webcast and replay and the earnings press release with financial and statistical information will be accessible in the Investors section at www.artivion.com under Webcasts & Presentations.

#AORT Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results

www.stocktitan.net/news/AORT/artivion-annou...

Artivion Reports Second Quarter 2025 Financial Results Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basis Net income was $1.3 million, or $0.03 per fully diluted share and non-GAAP net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025...

#AORT Artivion Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/AORT/artivion-repor...

Leading Cardiac Surgery Company Artivion Sets Q2 2025 Earnings Release Date Join CEO Pat Mackin for Artivion's Q2 2025 results on August 7. Live webcast and call details available for this cardiac surgery leader. Get insights.

#AORT Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results

www.stocktitan.net/news/AORT/artivion-annou...

İstanbul Gazetem’in imtiyaz sahibi, gazeteci Varol Kısa (E-?) İstanbul’da, aort yırtılması sonucu yaşamını yitirdi.
www.olumhaberi.com/istanbul-gaz... #İstanbulGazetem #gazeteci #VarolKisa #istanbul #vefat #cenaze #aort

Artivion Inc. Set to Showcase Innovations at Two Investor Conferences Artivion, Inc. announces its participation in two significant investor conferences focused on cardiac and vascular surgery, featuring key presentations.

Artivion Inc. Set to Showcase Innovations at Two Investor Conferences #USA #Atlanta #Artivion #Cardiac_Surgery #AORT

Artivion Slashes Debt: $95M Notes Converting to 4.1M Shares in Strategic Financial Move Major debt restructuring sees Artivion exchange $95M of convertible notes for equity. Calculate potential dilution impact and see how this reshapes the balance sheet. Get details.

#AORT Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

www.stocktitan.net/news/AORT/artivion-annou...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Tue May 6th - #TOPP #VSA #TDUP #SLGL #RGC #MRIN #HTRX #GLMD #FARO #EVGO #DHC #AORT #EQV #CCLD #BTMD #IHS #IPI #VCSA #FOXO #ADN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Artivion Beats Q1 Expectations: Stent Grafts Surge 14%, Company Raises Full-Year Revenue Target Artivion posts $99M revenue, lifts 2025 guidance amid strong stent graft and On-X growth. See full earnings details and positive NEXUS trial data.

#AORT Artivion Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/AORT/artivion-repor...

Breakthrough Aortic Treatment Cuts Major Complications by 63% in FDA Trial, Transforming High-Risk Patient Care New clinical data reveals significant reduction in adverse events for minimally invasive aortic arch treatment. FDA trial demonstrates superior outcomes for high-risk patients. See results.

#AORT Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

www.stocktitan.net/news/AORT/artivion-annou...

Artivion Celebrates Strong Financial Results for 2024 with Significant Revenue Growth Artivion, a leader in cardiac and vascular surgery, reports impressive financial growth for the fourth quarter and full year 2024, highlighting advances in technology.

Artivion Celebrates Strong Financial Results for 2024 with Significant Revenue Growth #United_States #Atlanta #Artivion #AMDS #AORT

Can Artivion's Bold 14% Growth Target Overcome Recent Setbacks? Q4 Earnings Deep Dive Strong product performance drives 10% full-year growth to $388.5M. Company targets $435M revenue for 2025 despite cyber incident, showcasing resilient growth trajectory.

#AORT Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/AORT/artivion-repor...

Artivion (AORT) Q4 Earnings Call: Strategic Growth Update & Financial Metrics Reveal - Mark Your Calendar Artivion to release Q4 and full-year 2024 financials on Feb 24, followed by CEO-led earnings call. Join the teleconference for complete insights.

#AORT Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/AORT/artivion-annou...

Artivion's AMDS Trial Shows 80% One-Year Survival Rate in Aortic Dissection Study Clinical trial data reveals breakthrough results for AMDS implant with zero DANE tears and significantly lower mortality vs. traditional treatments. FDA approval expected 2025.

#AORT Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting

www.stocktitan.net/news/AORT/artivion-annou...

Artivion's Revolutionary Aortic Device Gets FDA Approval, Shows 72% Drop in Mortality Artivion's AMDS Hybrid Prosthesis receives FDA humanitarian approval for treating acute aortic dissections, demonstrating breakthrough mortality reduction in clinical trials.

#AORT Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

#stocks #StockMarket #investing

www.stocktitan.net/news/AORT/artivion-grant...

WBD: Warner Bros Discovery Inc Stock Price Quote - NASDAQ GS - Bloomberg Stock analysis for Warner Bros Discovery Inc (WBD:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

#AORT announces direct stock offering aiming to raise approximately $1M. This move aims to make the stock more affordable for investors. Stay tuned for more updates on this exciting development! #stockmarket #investment

www.bloomberg.com/quote/WBD:US

#AORT #HQY #CPAY #PKG
Tickers to consider to invest today.
All of them signaling #StrongBuy
For all of them #Sentimentscore above 0.995

Just In: ( NYSE: #AORT ) Market Outperform Recommendation Issued On AORT By JMP Securities

#StockMarket #News